Combined modality therapy for stage III(MO) non-oat cell bronchogenic carcinoma

J. D. Bitran, R. K. Desser, T. DeMeester, C. M. Shapiro, A. Billings, L. Rubenstein, R. Evans, M. Colman, C. Y. Rao, M. Griem, H. M. Golomb

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Thirty-nine patients with stage III (MO) non-oat cell bronchogenic carcinoma (NOBC) were treated with combined modality therapy: radiation therapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, and procarbazine. The median survival for all patients treated was 9.6 months compared to 6.4 months for historical controls (P = 0.015). Patients who responded to the treatment program had a significantly longer survival (median, 15.2 months) compared to nonresponders and historical controls (P < 0.005). It is concluded that combined modality therapy is moderately effective therapy in stage III (MO) NOBC.

Original languageEnglish
Pages (from-to)327-332
Number of pages6
JournalCancer Treatment Reports
Volume62
Issue number3
StatePublished - 1978
Externally publishedYes

Fingerprint

Combined Modality Therapy
Bronchogenic Carcinoma
Procarbazine
Survival
Methotrexate
Doxorubicin
Cyclophosphamide
Radiotherapy
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bitran, J. D., Desser, R. K., DeMeester, T., Shapiro, C. M., Billings, A., Rubenstein, L., ... Golomb, H. M. (1978). Combined modality therapy for stage III(MO) non-oat cell bronchogenic carcinoma. Cancer Treatment Reports, 62(3), 327-332.

Combined modality therapy for stage III(MO) non-oat cell bronchogenic carcinoma. / Bitran, J. D.; Desser, R. K.; DeMeester, T.; Shapiro, C. M.; Billings, A.; Rubenstein, L.; Evans, R.; Colman, M.; Rao, C. Y.; Griem, M.; Golomb, H. M.

In: Cancer Treatment Reports, Vol. 62, No. 3, 1978, p. 327-332.

Research output: Contribution to journalArticle

Bitran, JD, Desser, RK, DeMeester, T, Shapiro, CM, Billings, A, Rubenstein, L, Evans, R, Colman, M, Rao, CY, Griem, M & Golomb, HM 1978, 'Combined modality therapy for stage III(MO) non-oat cell bronchogenic carcinoma', Cancer Treatment Reports, vol. 62, no. 3, pp. 327-332.
Bitran JD, Desser RK, DeMeester T, Shapiro CM, Billings A, Rubenstein L et al. Combined modality therapy for stage III(MO) non-oat cell bronchogenic carcinoma. Cancer Treatment Reports. 1978;62(3):327-332.
Bitran, J. D. ; Desser, R. K. ; DeMeester, T. ; Shapiro, C. M. ; Billings, A. ; Rubenstein, L. ; Evans, R. ; Colman, M. ; Rao, C. Y. ; Griem, M. ; Golomb, H. M. / Combined modality therapy for stage III(MO) non-oat cell bronchogenic carcinoma. In: Cancer Treatment Reports. 1978 ; Vol. 62, No. 3. pp. 327-332.
@article{9f354b5110ae428e82270153bb17dcae,
title = "Combined modality therapy for stage III(MO) non-oat cell bronchogenic carcinoma",
abstract = "Thirty-nine patients with stage III (MO) non-oat cell bronchogenic carcinoma (NOBC) were treated with combined modality therapy: radiation therapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, and procarbazine. The median survival for all patients treated was 9.6 months compared to 6.4 months for historical controls (P = 0.015). Patients who responded to the treatment program had a significantly longer survival (median, 15.2 months) compared to nonresponders and historical controls (P < 0.005). It is concluded that combined modality therapy is moderately effective therapy in stage III (MO) NOBC.",
author = "Bitran, {J. D.} and Desser, {R. K.} and T. DeMeester and Shapiro, {C. M.} and A. Billings and L. Rubenstein and R. Evans and M. Colman and Rao, {C. Y.} and M. Griem and Golomb, {H. M.}",
year = "1978",
language = "English",
volume = "62",
pages = "327--332",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Combined modality therapy for stage III(MO) non-oat cell bronchogenic carcinoma

AU - Bitran, J. D.

AU - Desser, R. K.

AU - DeMeester, T.

AU - Shapiro, C. M.

AU - Billings, A.

AU - Rubenstein, L.

AU - Evans, R.

AU - Colman, M.

AU - Rao, C. Y.

AU - Griem, M.

AU - Golomb, H. M.

PY - 1978

Y1 - 1978

N2 - Thirty-nine patients with stage III (MO) non-oat cell bronchogenic carcinoma (NOBC) were treated with combined modality therapy: radiation therapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, and procarbazine. The median survival for all patients treated was 9.6 months compared to 6.4 months for historical controls (P = 0.015). Patients who responded to the treatment program had a significantly longer survival (median, 15.2 months) compared to nonresponders and historical controls (P < 0.005). It is concluded that combined modality therapy is moderately effective therapy in stage III (MO) NOBC.

AB - Thirty-nine patients with stage III (MO) non-oat cell bronchogenic carcinoma (NOBC) were treated with combined modality therapy: radiation therapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, and procarbazine. The median survival for all patients treated was 9.6 months compared to 6.4 months for historical controls (P = 0.015). Patients who responded to the treatment program had a significantly longer survival (median, 15.2 months) compared to nonresponders and historical controls (P < 0.005). It is concluded that combined modality therapy is moderately effective therapy in stage III (MO) NOBC.

UR - http://www.scopus.com/inward/record.url?scp=0018152329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018152329&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 327

EP - 332

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -